Findings

What do systematic reviews say?

8 questions · 8 findings · 6 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 4 · 50%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 37.5%Moderate 0 · 0%High 1 · 12.5%

Phaco‐AIT vs Phaco‐Trab

Mean change in health‐related quality of life · people with open‐angle glaucoma

The review found no eligible studies for this question.

1 finding from 1 review

Ab interno trabecular bypass surgery with Trabectome for open‐angle glaucoma 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Phacoemulsification + supraciliary microstent surgery vs phacoemulsification alone

Mean change in health‐related quality of life · people with open‐angle glaucoma

The review found no eligible studies for this question.

1 finding from 1 review

Ab interno supraciliary microstent surgery for open‐angle glaucoma 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hydrus microstent vs iStent trabecular micro‐bypass stent

Mean change in health‐related quality of life · people with open angle glaucoma, many of whom had mild or moderate glaucoma, which was well‐controlled with medication

The review found no eligible studies for this question.

1 finding from 1 review

Ab interno trabecular bypass surgery with Schlemm´s canal microstent (Hydrus) for open angle glaucoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Cataract surgery with Hydrus microstent vs cataract surgery alone

Mean change in health‐related quality of life · people with cataracts and open angle glaucoma, many of whom had mild or moderate glaucoma, which was well‐controlled with medication

The review found no eligible studies for this question.

1 finding from 1 review

Ab interno trabecular bypass surgery with Schlemm´s canal microstent (Hydrus) for open angle glaucoma 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sorafenib vs pazopanib (targeted agent versus targeted agent)

Health‐related quality of life (mean change value) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 267 participants
Low

Pazopanib vs sunitinib (targeted agent versus targeted agent)

Health‐related quality of life (mean change value) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)

1 finding from 1 review

Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 467 participants
Low

Summary of findings table ‐ Cannabis vs placebo

Health‐related quality of life. Mean change from baseline · health problem or population

1 finding from 1 review

Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis 2022 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 1942 participants
Low

Ataluren vs placebo

Quality of life: CFQ‐R respiratory domain: absolute change from baseline · adults and children with CF with at least one class I mutation (PTC)

1 finding from 1 review

Ataluren and similar compounds (specific therapies for premature termination codon class I mutations) for cystic… 2023 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 506 participants
High